Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database

@article{Kane2011TwelveMonthPW,
  title={Twelve-Month Persistency with Oral 5-Aminosalicylic Acid Therapy for Ulcerative Colitis: Results from a Large Pharmacy Prescriptions Database},
  author={Sunanda V Kane and Michael Sumner and Dory Solomon and Matthew Jenkins},
  journal={Digestive Diseases and Sciences},
  year={2011},
  volume={56},
  pages={3463-3470}
}
BackgroundPatients receiving 5-aminosalicylic acid (5-ASA) require long-term therapy to achieve good outcomes. Persistency (duration of time from initiation to discontinuation of therapy) is therefore an important consideration.AimTo evaluate persistency in patients receiving various oral 5-ASA formulations.MethodsThis retrospective, 12-month, cohort study examined new-starter patients (any age and diagnosis) from a large United States pharmacy database who filled a prescription for oral 5-ASA… Expand
Medication use patterns and predictors of nonpersistence and nonadherence with oral 5-aminosalicylic acid therapy in patients with ulcerative colitis.
TLDR
Evaluating 5-ASA medication use patterns and risk factors associated with nonpersistence and nonadherence to oral 5- ASA medications in UC patients found patients on Multi-Matrix System mesalamine were less likely to discontinue and more likely to adhere to their medication. Expand
Long-term Compliance with Oral 5-aminosalicylic Acid Therapy and Risk of Disease Recurrence in Patients with Ulcerative Colitis: A Population-based Cohort Study
TLDR
This unselected cohort study revealed a reverse association between compliance and recurrence of ulcerative colitis, unlikely to be explained by severe confounding because the authors were able to adjust for several demographic and clinical factors. Expand
5-Aminosalicylate Therapy
TLDR
The use of 5-ASAs in adults with IBD is well established; however, there is limited evidence for their safety and efficacy in the pediatric IBD population, and this shortcoming is further accentuated by mounting evidence that suggests important differences between adult and Pediatrics IBD. Expand
Long-term efficacy and safety of once-daily mesalazine granules for the treatment of active ulcerative colitis
TLDR
It was not possible to detect differences in adherence between OD and multiple dose regimens in the clinical trial setting, and patents for minor changes to the formulation may serve as protection against drug companies trying to launch generic versions. Expand
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine
  • K. Nanda, A. Moss
  • Medicine
  • Clinical pharmacology : advances and applications
  • 2012
TLDR
The use of such once-daily formulations has led to intense interest in whether simplified pill regimens can improve patient adherence to mesalamine therapy, and the overall safety profile of MMX mesalamines is similar to other oral Mesalamine formulations. Expand
Update on the management of ulcerative colitis: treatment and maintenance approaches focused on MMX® mesalamine. [Corrigendum]
  • K. Nanda, A. Moss
  • Medicine
  • Clinical pharmacology : advances and applications
  • 2013
TLDR
Mesalamine with Multi-Matrix System (MMX) technology is an oral (1.2 g), once-daily tablet formulation of mesalamine used for the treatment of UC and effectively induced and maintained clinical remission in patients with active mild-to-moderate UC. Expand
A Random Urine Test Can Identify Patients at Risk of Mesalamine Non-Adherence: A Prospective Study
TLDR
A random urine salicylate level measured in the clinic can identify patients who have not recently taken mesalamine, and who are at higher risk of longitudinal non-adherence, and could be used to screen patients who may warrant interventions to improve adherence and prevent disease relapse. Expand
eHealth: Individualization of Mesalazine Treatment Through a Self-managed Web-based Solution in Mild-to-moderate Ulcerative Colitis
TLDR
The study confirms mesalazine efficacy in mild-to-moderate UC, significantly improving TIBS values in majority of the patients and helps to individualize the dose and improve adherence to therapy. Expand
Role of pharmacoepidemiology studies in addressing pharmacovigilance questions: a case example of pancreatitis risk among ulcerative colitis patients using mesalazine
TLDR
Findings of no increase in pancreatitis risk with MMX mesalazine demonstrate the value of pharmacoepidemiology studies for evaluating a drug’s postmarket safety profile when confronted with spontaneous reporting data suggestive of a safety issue. Expand
Remission in Pediatric Inflammatory Bowel Disease Correlates With Prescription Refill Adherence Rates
TLDR
Use of PBM databases to identify and intervene on patients with poor adherence may improve outcomes in pediatric IBD and find a significant association between refill adherence and clinical remission. Expand
...
1
2
3
...

References

SHOWING 1-10 OF 46 REFERENCES
A practical perspective on ulcerative colitis: Patients' needs from aminosalicylate therapies
  • E. Loftus
  • Medicine
  • Inflammatory bowel diseases
  • 2006
TLDR
It is demonstrated that continuous symptomatic remission is central to patient satisfaction and that patients find currently available aminosalicylates to be inconvenient, and development of such a therapy would improve both patient compliance and overall treatment success. Expand
Prevalence of nonadherence with maintenance mesalamine in quiescent ulcerative colitis
TLDR
Outpatients with clinically quiescent ulcerative colitis for 6 months on maintenance mesalamine and a history of more than four prescriptions, male gender, and single status and stratified analysis and regression modeling identified nonadherence as the outcome of interest. Expand
Medication nonadherence and the outcomes of patients with quiescent ulcerative colitis.
TLDR
Nonadherence with medication increases the risk of clinical relapse among patients with quiescent ulcerative colitis and future research should be directed at behavioral interventions to improve adherence. Expand
Medication-Taking Behavior in a Cohort of Patients with Inflammatory Bowel Disease
TLDR
The only factor associated with a better adherence was a more complicated course of the disease—steroid dependency, steroid refractoriness, need for infliximab treatment, hospitalization, or surgery (P=.02). Expand
Medication Non-adherence is Associated with Increased Medical Health Care Costs
TLDR
Non-adherence to 5-aminosalicylic acid (5-ASA) is associated with higher health care costs for both in- and outpatient settings, and patients need to be educated regarding non-adherent and increased costs. Expand
Nonadherence in inflammatory bowel disease: Results of factor analysis
TLDR
The overall intentional nonadherence with medical therapy is relatively high among patients with Crohn's disease and ulcerative colitis and should be taken into account when a patient's response to treatment is unsatisfactory. Expand
Compliance to therapy in patients on a maintenance dose of sulfasalazine.
TLDR
It is indicated that a substantial number of patients on maintenance therapy with SASP do not take the prescribed dose and drug trials in these patients should therefore incorporate methods of detecting defaulters. Expand
Compliance to therapy in patients on a maintenance dose of sulfasalazine.
TLDR
It is indicated that a substantial number of patients on maintenance therapy with SASP do not take the prescribed dose and drug trials in these patients should therefore incorporate methods of detecting defaulters. Expand
A gap analysis approach to assess patient persistence with glaucoma medication.
TLDR
Compared with Kaplan-Meier survival curves, the gap analysis approach may better parallel clinical experience with patient persistence, in which patients stop and restart medications for a variety of reasons over time. Expand
Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
TLDR
Patients initiating treatment with branded escitalopram were more likely to continue and less likely to switch or augment treatment at 2 and 6 months of therapy compared with those who initiated with alternative SSRIs. Expand
...
1
2
3
4
5
...